A case report of deferasirox-induced kidney injury and Fanconi syndrome.

Noreen Murphy, Mohsen Elramah, Hemender Vats, Weixong Zhong, Micah R Chan

Journal: WMJ : official publication of the State Medical Society of Wisconsin 2014;112(4):177-80

PMID: 24734408

Free Full Text on Wisconsin Medical Journal View on PubMed

Abstract

Cases of kidney injury associated with the use of deferasirox chelation therapy during the course of treatment for iron overload have been reported infrequently. We present the case of a patient treated with deferasirox who had biopsy-proven tubular injury in the setting of clinical Fanconi syndrome. The patient required hospitalization for metabolic acidosis, electrolyte abnormalities, and associated symptoms. With supportive care and cessation of chelation therapy he improved, but has yet to fully recover. This is the first known case reporting biopsy-proven tubular damage in the setting of deferasirox use.

Link outs

Free resources

Full Text Sources:

https://wmjonline.org/wp-content/uploads/2013/112/...

Subscription / membership required

Other Literature Sources:

https://facultyopinions.com/pubmed/24734408

MeSH Terms: Benzoates, Deferasirox, Fanconi Syndrome, Humans, Iron Chelating Agents, Iron Overload, Male, Renal Insufficiency, Triazoles, Young Adult